A long-acting somatostatin octapeptide delivered as an extended-release depot.
Also known as: Somatuline
Part of the Foundational & therapeutic peptides cluster
Overview
Lanreotide is a synthetic octapeptide analog of somatostatin that binds the same inhibitory receptors but resists degradation for far longer than the native hormone. It is an approved therapeutic for acromegaly and gastroenteropancreatic neuroendocrine tumors. This page is educational and not medical advice.
Source & context
Biological / chemical source: Synthetic octapeptide analog of somatostatin
Primary research or clinical context: Approved for acromegaly and gastroenteropancreatic neuroendocrine tumors
Somatostatin mimicry
By activating somatostatin receptor subtypes, lanreotide suppresses growth hormone and multiple gut hormones. Shortening and stabilizing the 14-residue native peptide into a cyclized octapeptide is a textbook example of turning a fleeting hormone into a durable drug.
Depot formulation
Lanreotide is supplied as a supersaturated gel depot that self-assembles under the skin, releasing peptide over several weeks. It sits alongside octreotide and pasireotide in the somatostatin-analog family used to control hormone-secreting tumors.
FAQ about Lanreotide
What is Lanreotide?+
Lanreotide is a synthetic octapeptide analog of somatostatin that binds the same inhibitory receptors but resists degradation for far longer than the native hormone. It is an approved therapeutic for acromegaly and gastroenteropancreatic neuroendocrine tumors. This page is educational and not medical advice.
Is Lanreotide an approved medicine?+
Lanreotide: Approved for acromegaly and gastroenteropancreatic neuroendocrine tumors. Always follow licensed medical guidance for approved products.
What is the typical length of Lanreotide?+
Lanreotide is commonly described as approximately 8 amino acids (Somatostatin analog).